Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- NRSN
- Price
- 0.94
- Stock movement down
- -0.03 (-2.79%)
- Company name
- Neurosense Therapeutics Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 27.78M
- Ent value
- 29.32M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -16.81%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NRSN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 29.55M |
| EPS (TTM) | -0.34 |
| FCF per share (TTM) | -0.00 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -8.57M |
| Net income (TTM) | -8.66M |
| EPS (TTM) | -0.34 |
| EPS (1y forward) | -0.18 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 666.00K |
| Net receivables | 847.00K |
| Total current assets | 1.56M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 105.00K |
| Total assets | 1.68M |
| Accounts payable | 1.09M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 2.20M |
| Total liabilities | 2.20M |
| Shareholder's equity | -519.00K |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -4.00K |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -4.00K |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -514.13% |
| Return on Invested Capital | 1668.21% |
| Cash Return on Invested Capital | 0.77% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.94 |
| Daily high | 0.99 |
| Daily low | 0.92 |
| Daily Volume | 325K |
| All-time high | 6.23 |
| 1y analyst estimate | 11.50 |
| Beta | 1.56 |
| EPS (TTM) | -0.34 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 25 Mar 2026 |
Downside potential
Loading...
Downside potential data
| NRSN | S&P500 | |
| Current price drop from All-time high | -84.91% | -0.89% |
| Highest price drop | -88.61% | -19.00% |
| Date of highest drop | 30 Dec 2025 | 8 Apr 2025 |
| Avg drop from high | -80.24% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
27.78M
Marketcap category
Small-cap
Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Employees
17
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page